Areteia Reports Positive Phase III Results

Areteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma

Areteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma Areteia Therapeutics, Inc. announced today that its Phase III EXHALE-4 clinical trial has met key efficacy and safety endpoints for dexpramipexole, an investigational oral therapy being developed as…

Read MoreAreteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma
Vertex Scientists Win 2025 Lasker~DeBakey Award

Vertex Scientists Win 2025 Lasker~DeBakey Award for Cystic Fibrosis Breakthroughs

Vertex Scientists Honored with Prestigious Lasker~DeBakey Award for Transformational Advances in Cystic Fibrosis Vertex Pharmaceuticals Incorporated announced today that Dr. Paul Negulescu, Senior Vice President, has been named a recipient of the 2025 Lasker~DeBakey Clinical Medical Research Award. Dr. Negulescu…

Read MoreVertex Scientists Win 2025 Lasker~DeBakey Award for Cystic Fibrosis Breakthroughs
Ferring Japan’s NDA for Nadofaragene Firadenovec Accepted by PMDA

Ferring Japan’s NDA for Nadofaragene Firadenovec Accepted by PMDA

Ferring Pharmaceuticals Co., Ltd. announced today that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has formally accepted the New Drug Application (NDA) for nadofaragene firadenovec, a novel non-replicating intravesical gene therapy developed for patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle…

Read MoreFerring Japan’s NDA for Nadofaragene Firadenovec Accepted by PMDA
Seaport Therapeutics Begins Phase 1 Trial of GlyphAgo™ (SPT-320)

Seaport Therapeutics Begins Phase 1 Trial of GlyphAgo™ (SPT-320)

Seaport Therapeutics a clinical-stage biopharmaceutical company developing next-generation neuropsychiatric medicines, announced that the first participant has been dosed in its Phase 1 clinical study of GlyphAgo™ (SPT-320 or Glyph Agomelatine). GlyphAgo is a novel “Glyphed” oral prodrug of agomelatine designed…

Read MoreSeaport Therapeutics Begins Phase 1 Trial of GlyphAgo™ (SPT-320)